The classical approach to decision-making in clinical research is the randomized trial. Patients are assigned to treatment conditions according to sample sizes that are determined a priori by power calculations. The data are not analyzed until the end of the study, at which time assignment codes are typically broken. Most clinical trials employ the Intent to Treat strategy which involves keeping all patients enrolled in the trial to its end. Positive decisions as to drug efficacy generally cannot be made until the study has been completed. Due to the cost and time involved in recruiting and processing subjects, size determination is extremely important. Unfortunately, this relies on two parameters that are rarely available during the study of new drugs – within-subject variability and the estimated magnitude of experimental effect.
NFC Forum Certified
IMC, the global leader in Smart Medication Adherence Solutions, is proud to announce that our Electronic Content Monitoring NFC Tag is the world's only Medication Adherence Device certified and listed by NFC Forum.
Our Electronic Content Monitors (ECMs) provide valuable and objective insights into medication adherence; we provide NFC Forum-certified devices, HIPAA cloud platform, apps and helpdesk services.
Our connected adherence devices are designed with the patient in mind. Our innovative medication technologies are available for blister packs, pill bottles, syringes and custom formats.
Did you know?
Utilizing NFC-connected smart adherence packaging optimizes your clinical decisions by improving data accuracy.